# ARVN PDUFA Calendar: FDA Decision Dates & Catalyst Timeline

Canonical URL: https://biopharmsignal.com/pdufa-calendar/ARVN
Company: Arvinas, Inc.

BioPharmSignal tracks active PDUFA and FDA decision milestones associated with ARVN.

## ARVN PDUFA Milestones

- 2026-05-01 — FDA Approval — FDA approved application. FDA recorded approval of VEPPANU (vepdegestrant) on May 1, 2026. This list-only historical record is sourced from the official FDA...
  Company: Arvinas, Inc.
  Source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
  Event detail: https://biopharmsignal.com/pdufa-calendar/ARVN/veppanu-vepdegestrant-veppanu-nda.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/may (May 2026)
- 2026-06-05 — PDUFA — FDA approved VEPPANU ahead of the PDUFA date. FDA approved vepdegestrant for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic brea...
  Company: Arvinas, Inc.
  Source: https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-fda-approval-veppanu-vepdegestrant-treatment/
  Event detail: https://biopharmsignal.com/pdufa-calendar/ARVN/veppanu-vepdegestrant-esr1-mutated-advanced-breast-cancer.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/june (June 2026)

## Related Pages

- Company page: https://biopharmsignal.com/company/ARVN
- Interactive PDUFA Calendar: https://biopharmsignal.com/pdufa-calendar

## FAQ

### What does the ARVN PDUFA calendar show?

It shows active PDUFA and FDA decision milestones associated with ARVN, including decision dates, application stage, and summary details when available.
### Where can I find more context for ARVN?

Use the BioPharmSignal company page for ARVN to read related news, stock data, sector context, and company-specific updates.
### Are these dates investment advice?

No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.